Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Quinn

Showing results (91-100 of 255) with videos related to

Pageof 26
Sort By:
Clinical Genitourinary Cancer|October 9, 2013
Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancerTanya B Dorff, Denice D Tsao-Wei, Susan Groshen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 21, 2013
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancerHossein Jadvar, Bhushan Desai, Lingyun Ji, et al.
Clinical Genitourinary Cancer|June 10, 2022
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell CarcinomaZizhen Feng, Brendan D Curti, David I Quinn, et al.
Anti-Cancer Drugs|April 28, 2009
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium studyPrimo N Lara, Jeff Longmate, Christopher P Evans, et al.
Urology|July 22, 2010
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium TrialPrzemyslaw Twardowski, Walter M Stadler, Paul Frankel, et al.
BJU International|August 5, 2011
Factors influencing post-recurrence survival in bladder cancer following radical cystectomyAnirban P Mitra, David I Quinn, Tanya B Dorff, et al.
The Journal of Urology|October 12, 2005
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastasesD Raghavan, L J Brandes, K Klapp, et al.
Prostate Cancer and Prostatic Diseases|March 4, 2020
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancerMitchell E Gross, David B Agus, Tanya B Dorff, et al.
BJU International|September 11, 2008
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancerJoseph S Chan, Tomasz M Beer, David I Quinn, et al.
Prostate Cancer and Prostatic Diseases|September 24, 2014
A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancerT B Dorff, S Groshen, D D Tsao-Wei, et al.
Pageof 26

Showing results (91-100 of 255) with videos related to

Sort By:
Pageof 26
Clinical Genitourinary Cancer|October 9, 2013
Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancerTanya B Dorff, Denice D Tsao-Wei, Susan Groshen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 21, 2013
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancerHossein Jadvar, Bhushan Desai, Lingyun Ji, et al.
Clinical Genitourinary Cancer|June 10, 2022
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell CarcinomaZizhen Feng, Brendan D Curti, David I Quinn, et al.
Anti-Cancer Drugs|April 28, 2009
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium studyPrimo N Lara, Jeff Longmate, Christopher P Evans, et al.
Urology|July 22, 2010
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium TrialPrzemyslaw Twardowski, Walter M Stadler, Paul Frankel, et al.
BJU International|August 5, 2011
Factors influencing post-recurrence survival in bladder cancer following radical cystectomyAnirban P Mitra, David I Quinn, Tanya B Dorff, et al.
The Journal of Urology|October 12, 2005
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastasesD Raghavan, L J Brandes, K Klapp, et al.
Prostate Cancer and Prostatic Diseases|March 4, 2020
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancerMitchell E Gross, David B Agus, Tanya B Dorff, et al.
BJU International|September 11, 2008
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancerJoseph S Chan, Tomasz M Beer, David I Quinn, et al.
Prostate Cancer and Prostatic Diseases|September 24, 2014
A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancerT B Dorff, S Groshen, D D Tsao-Wei, et al.
Pageof 26